Literature DB >> 7058762

Pharmacokinetics of diltiazem in selected animal species and human beings.

R W Piepho, D C Bloedow, J P Lacz, D J Runser, D C Dimmit, R K Browne.   

Abstract

The absorption, distribution and elimination of diltiazem hydrochloride in rodent and canine species are reviewed. The drug is well absorbed but undergoes first pass metabolism after oral administration. Diltiazem is extensively distributed, and 52 to 81 percent is bound to serum protein, depending on the species studied. Diltiazem is metabolized in the liver by several pathways; deacetylation, N-demethylation, and O-demethylation are the primary degradative steps. The metabolites are excreted in urine and feces, indicating that biliary excretion occurs. There is some evidence for enterohepatic cycling. Diltiazem is rapidly eliminated (t 1/2 = 2.24 hours) in beagle dogs, and the relatively short half-life appears to be a result of the high level of plasma clearance (46.1 +/- 4.8 ml/min/per kg body weight). A comparison of the plasma diltiazem clearance with hepatic blood flow in the dog indicates that the drug is eliminated at a rate dependent on hepatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7058762     DOI: 10.1016/s0002-9149(82)80006-4

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  13 in total

1.  Performance of diltiazem tablet and multiparticulate osmotic formulations in the dog.

Authors:  S C Sutton; K Engle; R A Deeken; K E Plute; R D Shaffer
Journal:  Pharm Res       Date:  1990-08       Impact factor: 4.200

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

Review 3.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

4.  Pharmacokinetics of diltiazem after intravenous and oral administration.

Authors:  P Hermann; S D Rodger; G Remones; J P Thenot; D R London; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 5.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

6.  N-monodesmethyldiltiazem is the predominant metabolite of diltiazem in the plasma of young and elderly hypertensives.

Authors:  S C Montamat; D R Abernethy
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

7.  Metabolism of diltiazem in hepatic and extrahepatic tissues of rabbits: in vitro studies.

Authors:  W Homsy; M Lefebvre; G Caillé; P du Souich
Journal:  Pharm Res       Date:  1995-04       Impact factor: 4.200

8.  Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

Authors:  G Caillé; S Boucher; J Spénard; Z Lakhani; A Russell; J Thiffault; M G Grace
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 9.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

Review 10.  Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine.

Authors:  P D Pearigen; N L Benowitz
Journal:  Drug Saf       Date:  1991 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.